Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs CAVA Group Inc (CAVA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs CAVA Group Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $221 (market cap $29.60B), while CAVA Group Inc trades at $68.22 (market cap $7.08B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 4.2× CAVA Group Inc's market cap, and CAVA Group Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | CAVA | |
|---|---|---|
Market Cap | $29.60B | $7.08B |
Sector | Health | Consumer Cyclical |
52-Week High | $491.22 | $97.39 |
52-Week Low | $205.48 | $43.59 |
Enterprise Value | $27.56B | $7.23B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About CAVA Group Inc
CAVA is a Mediterranean fast-casual restaurant brand in the US. It offers customizable bowls, salads, and pitas featuring healthy ingredients, while also selling its signature dips and dressings in grocery stores.
Read more on CAVA →
